Post by iOMEDICO

𝗡𝗲𝘄 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: 𝗳𝗶𝗻𝗮𝗹 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗿𝗼𝗺 𝗙𝗜𝗥𝗦𝗧-𝗡𝗜𝗦 We are pleased to share the publication of the final results from the prospective, non-interventional study FIRST-NIS, evaluating the use of lenalidomide plus low-dose dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma in Germany. The study included 168 patients with a median age of 77.7 years.   𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: •    median PFS: 22.9 months •    median OS: 58.1 months •    quality of life was maintained during treatment •    no new safety signals were observed   At iOMEDICO, we see prospective real-world research as a valuable way to complement clinical trial data with insights from routine care. We thank all investigators, study sites and patients who contributed to this work. #MultipleMyeloma #RealWorldData #ClinicalResearch #Oncology #Hematology #iOMEDICO #MultipleMyeloma #RealWorldData #RWD #ClinicalResearch #CancerResearch #Oncology #Hematology #BloodCancer #CRO #iOMEDICO